Peter Smibert

I'm really thrilled to share what I've been working on the past year! We hope this method represents a step towards democratizing single-cell screens, and helps to make it possible to run genome-wide scale experiments routinely. Check out our tweetorial and the preprint here 👇

Excited to share VIPerturb-seq! New tech from my lab which aims to improve the cost, data quality, and efficiency of single-cell CRISPR screens so that they are accessible to any lab - even at genome-wide scale Preprint and 🧵 (1/): biorxiv.org/content/10.648…

And another one. ☝️ Last week: ProPer-seq. This week: VIPerturb-seq from the Satija Lab. Paper after paper is proving @10xGenomics Flex is the definitive engine for genome-scale perturbation screens. The new stats are wild: 🚀 440,000 cells per lane 🚀 50x throughput boost 🚀 65% more genes detected/cell Routine genome-scale screens are here. #singlecell #genomics #CRISPR #biotech #10xGenomics #virtualcell

We put a blog post together to tell you about all that went behind the scenes for @arcinstitute's Virtual Cell Challenge: (1) the modality used for genetic perturbations, (2) choice of single cell RNA seq chemistry, (3) which cell line to use for the challenge, (4) which genes to perturb, (5) the quality considerations for the resulting dataset, and (6) how we defined performance metrics for perturbation predictions.

Smaller studies? We’ve got you covered. New 8-sample #singlecell kits for Universal 3’ & 5’, plus lower prices: bit.ly/4fK417l

Excited to announce that we're becoming part of 10x Genomics! This acquisition will validate our team's incredible work and scales our impact in single cell innovation, bringing even greater value to our research community. Here's to the next phase! hubs.la/Q03BRN0B0

Big news in single cell! @10xGenomics agrees to acquire @scalebio. Read my exclusive here. genengnews.com/topics/omics/1…

Ideas aren’t just born fully mature into commercial realization. They require refinement, testing, well-integrated teams, and, moreover, a need for their purpose. I am thrilled, therefore, to announce the acquisition of Scale Biosciences by 10X Genomics. I co-founded Scale Bio with Frank Steemers (formerly of Illumina), along with Professors Jay Shendure & Cole Trapnell (University of Washington). Together, we integrated quantum bar coding and combinatorial indexing technologies for single-cell analysis of protein, gene expression, and epigenetics at the multi-million cell scale. We join now with the technological and global reach of 10x Genomics. I am incredibly excited to join 10x Genomics as a scientific advisor to amplify the broad-scale application of these ideas to researchers and patients worldwide. There is near limitless value in the data suite now produced by combined technologies at 10x that, along with the rapidly enabling landscape of artificial intelligence, will bring exciting new insights, and thereby therapies, across a range of biomedical needs. It’s an exciting time to be in the biosciences, watching as ideas evolve from scribblings on paper to helping patients!

This acquisition will bring together two pioneering companies with a shared vision: to make single cell analysis more powerful, affordable and accessible to researchers worldwide. Learn more: bit.ly/4mru4lK

New #singlecell benchmarking data is here! The team @HutchInnovation has been hard at work comparing the latest assays. Read the preprint for all the data and see how top-performing Flex and Universal assays can make a huge difference in your research: bit.ly/4569a6l

We are pleased to share our work evaluating some of the latest single-cell platforms, including updated chemistries, in two separate experiments using peripheral blood mononuclear cells (PBMCs). biorxiv.org/cgi/content/sh…

🧬 We’re excited to introduce D&D-seq, a single-cell technology that maps DNA:Protein interactions through molecular footprinting.. Check it out here: biorxiv.org/content/10.110… #Genomics #Epigenetics

In collaboration with Reuben Saunders, @JswLab, and Xiaowei Zhuang, we are very excited to release Perturb-Multi: a platform for pooled multimodal genetic screens in intact mammalian tissue. Check it out! biorxiv.org/content/10.110…

One key component of Perturb-Multi is in vivo Perturb-seq of formaldehyde-fixed tissue, enabled by the Flex reagents from @10xGenomics.

Comparison of Fixed Single Cell RNA-seq Methods to Enable Transcriptome Profiling of Neutrophils in Clinical Samples biorxiv.org/cgi/content/sh… #biorxiv_genomic

doi.org/10.1038/s41587… @NatureBiotech Important benchmarking, code and #data from #PBMCs, across platforms. @10xGenomics does well Reassuringly consistent cell estimates of DARs (differentially accessible regions)

Tune in tomorrow to see @tsion_abay present her work on PERFF-seq, a novel method for enriching for specific cell types and states upstream of @10xGenomics' Flex assay. 10xgenomics.com/blog/from-rare…

@lucksmith @MSKCancerCenter @nygenome @10xGenomics You're too kind. Was great to see you and Betsy and hear about all the cool stuff that's in the works.

so rewarding to see trainees flourish and change the world. just saw @psmibert, in our lab @MSKCancerCenter he discovered fundamental miRNA and APA mechanisms, then Director of Tech Innovation @nygenome invented CITE-seq and pub dozens elite papers, now VP Biology @10xGenomics!!

GoT-ChA! I am thrilled to announce that our paper "Mapping Genotypes to Chromatin Accessibility Profiles in Single Cells" is now out in @Nature !! 👩‍🔬👨‍🔬🧬If you want to link somatic mutations to epigenetic changes directly in patient samples: nature.com/articles/s4158… 👇🧵

#FixNCut, a method for early sample preservation to overcome current limitations in Single-cell omics | ⁦@cnag_eu⁩ ⁦@ACEpigenetics⁩ ⁦@UniofAdelaide⁩ ⁦@StJudeResearch⁩ ⁦@OmniscopeAI⁩ ⁦@SAiGENCI⁩ ⁦@PeterMacCC⁩ cnag.eu/news/fixncut-n…